MAYO CLINIC LABORATORIES

1-800-533-1710

BIVAL

Bivalirudin, Ecarin, Plasma

Patient ID	Patient Name		Birth Date	Gender	Age
SA00145708	TESTINGRNV, BIVAL		1981-01-01	M	40
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00145708	SA00145708	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		02 Aug 2021 00:00			

Bivalirudin, Ecarin, P

Result Name	Value	Unit	Reference Value	Performing Site
High **Bivalirudin, Ecarin, P**	**0.15**	mcg/mL	<0.10	[1] MCR

Interpretation

MCR

Internal laboratory validation demonstrates that plasma concentrations of Bivalirudin 0.25 to 2.00 mcg/mL correspond to an aPTT ratio of 1.5–3.0.

Cautions

MCR

NOTE: Correlation of bivalirudin drug concentrations with aPTT ratios may vary with different aPTT reagents. This assay is not indicated for monitoring low molecular weight heparin (LMWH), unfractionated heparin (UFH) or oral direct anti-Xa inhibitors (e.g. apixaban, rivaroxaban, edoxaban). Presence of lipemia could falsely increase bivalirudin levels; presence of marked hemolysis or bilirubin in the sample could falsely decrease bivalirudin levels. This assay is not intended for measurement of dabigatran or argatroban drug concentrations. Data correlating clinical outcomes based on bivalirudin drug concentrations are lacking.

Received: 03 Aug 2021 16:49 **Reported:** 03 Aug 2021 16:52

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292